PDF(820 KB)
Effect of downregulating proline-rich protein 11 expression on drug resistance of esophageal cancer drug resistant cell EC9706/DDP and its mechanism
Chunyan KANG,Xiuzhi ZHANG,Huicong ZHOU,Jie CHEN
PDF(820 KB)
PDF(820 KB)
Effect of downregulating proline-rich protein 11 expression on drug resistance of esophageal cancer drug resistant cell EC9706/DDP and its mechanism
)Objective To discuss the effect of downregulating the proline-rich protein 11 （PRR11） expression on drug resistance of the esophageal cancer drug resistant cells， and to clarify the related mechanism. Methods The drug resistant cells EC9706/cisplatin（DDP） were established by incrementally stimulating the human esophageal cancer EC9706 cells with the increasing concentrations of DDP. The drug sensitivity of the EC9706/DDP cells was detected by MTT assay； the expression levels of PRR11 mRNA and protein in the EC9706/DDP cells and their parent EC9706 cells were detected by real-time fluorescence quantitative PCR （RT-qPCR） and Western blotting methods. The EC9706/DDP cells were divided into control group，sh-NC group （infected with sh-NC），sh-PRR11 group（infected with sh-PRR11）， sh-NC+DDP group （infected with sh-NC and treated with 4 mg·L－1 DDP）， and sh-PRR11+DDP group （infected with sh-PRR11 and treated with 4 mg·L－1 DDP）. The expression levels of PRR11 mRNA in the cells in various groups were detected by RT-qPCR method； the expression levels of PRR11， phosphoinositide 3-kinase （PI3K） p110α， protein kinase B （AKT）， phosphorylated AKT （p-AKT）， P-glycoprotein （P-gp）， and multidrug resistance-associated protein 1 （MRP1） proteins in the cells in various groups were detected by Western blotting method；the apoptotic rates of the cells in various groups were detected by flow cytometry. Results The DDP-resistant cell line EC9706/DDP was successfully obtained，and the drug resistance index was 7.23±0.86. Compared with the EC9706 cells， the expression levels of PRR11 mRNA and protein in the EC9706/DDP cells were increased （P<0.05）. Compared with control and sh-NC groups， the expression levels of PRR11 mRNA and protein in the cells in sh-PRR11 group were decreased （P<0.05），and the 50% inhibitory concentration （IC50） of DDP was decreased （P<0.05）.Compared with sh-NC group，the expression levels of PI3K p110α， p-AKT， P-gp， and MRP1 proteins in the cells in sh-NC+DDP and sh-PRR11 groups were decreased （P<0.05），and the apoptotic rate of the cells was increased （P<0.05）. Compared with sh-NC+DDP group and sh-PRR11 group，the expression levels of PI3K p110α， p-AKT， P-gp， and MRP1 proteins in the cells in sh-PRR11+DDP group were increased（P<0.05），and the apoptotic rate of the cells was increased（P<0.05）. Conclusion Downregulating the expression of PRR11 gene in the drug resistant EC9706/DDP cells can inhibit the expressions of drug resistance-related proteins， reverse the resistance to DDP， and induce the apoptosis； its mechanism may be related to the inhibition of activation of the PI3K/AKT signaling pathway.
Proline-rich protein 11 / Esophageal neoplasm / Cisplatin / Drug resistance / Phosphoinositide 3-kinase/protein kinase B signaling pathway
R735.1
| 1 | LI Q， LIU T， DING Z Y. Neoadjuvant immunotherapy for resectable esophageal cancer： a review［J］. Front Immunol， 2022， 13： 1051841. |
| 2 | GHOSH N R， JONES L A. Dietary risk factors for esophageal cancer based on World Health Organization regions［J］. Nutrition， 2022， 95： 111552. |
| 3 | LOHAN-CODE?O M， BARAMBO-WAGNER M L， NASCIUTTI L E， et al. Molecular mechanisms associated with chemoresistance in esophageal cancer［J］. Cell Mol Life Sci， 2022， 79（2）： 116. |
| 4 | GIACOMINI I， RAGAZZI E， PASUT G， et al. The pentose phosphate pathway and its involvement in cisplatin resistance［J］. Int J Mol Sci， 2020， 21（3）： 937. |
| 5 | 陈 洁， 亢春彦， 杨红梅， 等. PRR11和SKA2在食管鳞癌中的表达及与临床预后的关系［J］. 临床与病理杂志， 2020， 40（2）： 302-309. |
| 6 | LI Z H， LI S W， WEN Y Q， et al. miR-495 inhibits cisplatin resistance and angiogenesis in esophageal cancer by targeting ATP7A［J］. Technol Cancer Res Treat， 2021， 20： 15330338211039127. |
| 7 | CHEN J， YANG H M， ZHOU H C， et al. PRR11 and SKA2 promote the proliferation， migration and invasion of esophageal carcinoma cells［J］. Oncol Lett， 2020， 20（1）： 639-646. |
| 8 | WANG C Y， YU L， REN X Y， et al. The oncogenic potential of PRR11 gene in tongue squamous cell carcinoma cells［J］. J Cancer， 2019， 10（11）：2541-2551. |
| 9 | LIN C J， XIA J， GU Z W， et al. Downregulation of USP34 inhibits the growth and migration of pancreatic cancer cells via inhibiting the PRR11［J］. Onco Targets Ther， 2020， 13： 1471-1480. |
| 10 | HAN W， CHEN L. PRR11 in malignancies： biological activities and targeted therapies［J］. Biomolecules， 2022， 12（12）： 1800. |
| 11 | MA H L， YANG W G， WANG X F， et al. PRR11 promotes proliferation and migration of colorectal cancer through activating the EGFR/ERK/AKT pathway via increasing CTHRC1［J］.Ann Clin Lab Sci，2022，52（1）： 86-94. |
| 12 | ZHONG F J， LIU S， HU D H， et al. LncRNA AC099850.3 promotes hepatocellular carcinoma proliferation and invasion through PRR11/PI3K/AKT axis and is associated with patients prognosis［J］. J Cancer， 2022， 13（3）： 1048-1060. |
| 13 | ZHOU L， DENG Z Z， LI H Y， et al. Overexpression of PRR11 promotes tumorigenic capability and is associated with progression in esophageal squamous cell carcinoma［J］. Onco Targets Ther， 2019， 12： 2677-2693. |
| 14 | WANG P， HU Y J， QU P P， et al. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway［J］. Bioengineered， 2022，13（1）： 1931-1941. |
| 15 | WU L J， CAI S Y， DENG Y Y， et al. PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression［J］. Int Immunopharmacol， 2021， 94： 107443. |
| 16 | ZHENG T L， LI D P， HE Z F， et al. miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway［J］. Cancer Cell Int， 2019， 19： 250. |
| 17 | DUAN W X， LIU X M. PSAT1 upregulation contributes to cell growth and cisplatin resistance in cervical cancer cells via regulating PI3K/AKT signaling pathway［J］. Ann Clin Lab Sci， 2020， 50（4）： 512-518. |
| 18 | GAO M H， LIU T， LI J N， et al. YAN， a novel microtubule inhibitor， inhibits P-gp and MRP1 function and induces mitotic slippage followed by apoptosis in multidrug-resistant A549/Taxol cells［J］. Toxicol In Vitro， 2020， 69： 104971. |
| 19 | ZHANG L， LI Y D， WANG Q C， et al. The PI3K subunits， P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer［J］. Mol Cancer， 2020， 19（1）： 10. |
| 20 | LEE K M， GUERRERO-ZOTANO A L， SERVETTO A， et al. Proline rich 11 （PRR11） overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer［J］. Nat Commun， 2020， 11（1）： 5488. |
| 21 | ZHU J， HU H， WANG J， et al. PRR11 overexpression facilitates ovarian carcinoma cell proliferation， migration， and invasion through activation of the PI3K/AKT/β-catenin pathway［J］. Cell Physiol Biochem， 2018， 49（2）： 696-705. |
/
| 〈 |
|
〉 |
AI Summary
